Scientifically estimated warranty provisions, grossed-up royalty tax and qualifying in-house research costs are described as deductible business expenditure.
Scientifically estimated warranty provisions based on historical trends are described as deductible trading expenditure under Section 37(1), where sale creates a present contractual obligation and expected costs are matched with recognised revenue. Withholding tax contractually borne by an assessee on a net-of-tax royalty payment is treated as part of the royalty consideration and allowable business expenditure. For in-house scientific research, Section 35(2AB) is described as requiring DSIR approval of the research facility, not certification of the expenditure amount; qualifying expenditure, excluding land or building costs, should therefore not be restricted to DSIR-quantified amounts. Consequential interest is stated to require recomputation.
Issues: (i) Whether scientifically estimated provision for warranty, based on historical trends, is deductible; (ii) Whether withholding tax borne by the assessee on a grossed-up royalty payment forms part of the deductible royalty consideration; (iii) Whether weighted deduction for in-house scientific research expenditure under Section 35(2AB) can be restricted to the expenditure quantified by DSIR.
Issue (i): Whether scientifically estimated provision for warranty, based on historical trends, is deductible.
Analysis: Warranty obligations arose upon sale and constituted present contractual obligations. The provision was made consistently using a scientific methodology based on historical experience and appropriately matched expected warranty costs with the revenue recognised under the mercantile system. An unutilised opening warranty provision could not, by itself, displace a provision otherwise supported by the established methodology and past trends.
Conclusion: The warranty provisions were legitimate trading expenditure deductible under Section 37(1) of the Income-tax Act, 1961, in favour of the assessee.
Issue (ii): Whether withholding tax borne by the assessee on a grossed-up royalty payment forms part of the deductible royalty consideration.
Analysis: The royalty arrangement required the assessee to discharge the non-resident parent's tax liability. Tax paid pursuant to that undertaking was part of the consideration payable for use of the intellectual property; absent that undertaking, the royalty consideration would have been correspondingly higher. The Settlement Commission's determination of the royalty amount did not determine the deductibility of the tax borne by the assessee.
Conclusion: The grossed-up withholding tax formed an integral part of the royalty cost and was allowable as business expenditure, in favour of the assessee.
Issue (iii): Whether weighted deduction for in-house scientific research expenditure under Section 35(2AB) can be restricted to the expenditure quantified by DSIR.
Analysis: Section 35(2AB) requires approval of the in-house research and development facility by DSIR, but does not require DSIR approval or certification of the quantum of eligible expenditure. The expression "any expenditure" covers qualifying scientific research expenditure incurred, other than the excluded cost of land or building. Quantification under Rule 6(7A) is preparatory to consideration of the deduction and does not restrict a claim where the approved facility and actual qualifying expenditure are undisputed.
Conclusion: The weighted deduction could not be restricted to the amount certified by DSIR, and the disallowed qualifying research expenditure was deductible, in favour of the assessee.
Final Conclusion: The assessment adjustments concerning warranty provisions, grossed-up royalty tax, and qualifying in-house research expenditure were unsustainable; consequential interest issues were to follow the revised computation.
Ratio Decidendi: A scientifically estimated warranty obligation arising from sales is deductible on accrual and matching principles; tax contractually borne on a net-of-tax royalty payment forms part of its consideration; and DSIR approval of an in-house research facility, rather than its expenditure quantification, governs eligibility for weighted deduction.